Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Purple Biotech American Depositary Shares Representing 200 Ord Shs PPBT

Healthcare
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi... see more

Recent & Breaking News (NDAQ:PPBT)

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire March 5, 2024

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

GlobeNewswire February 27, 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

GlobeNewswire February 13, 2024

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

GlobeNewswire February 1, 2024

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

GlobeNewswire December 20, 2023

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

GlobeNewswire December 14, 2023

Purple Biotech Reports Third Quarter 2023 Financial Results

GlobeNewswire November 21, 2023

Purple Biotech Fortifies NT219 Patent Protection

GlobeNewswire November 2, 2023

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

GlobeNewswire October 19, 2023

Purple Biotech Announces $5 Million Registered Direct Offering

GlobeNewswire October 17, 2023

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

GlobeNewswire October 6, 2023

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

GlobeNewswire October 3, 2023

Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023

GlobeNewswire September 21, 2023

Purple Biotech Reports Second Quarter 2023 Financial Results

GlobeNewswire August 22, 2023

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

GlobeNewswire July 11, 2023

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 16, 2023

Purple Biotech Debuts Scientific Advisory Board

GlobeNewswire April 25, 2023

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

GlobeNewswire April 19, 2023

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

GlobeNewswire April 18, 2023

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

GlobeNewswire March 24, 2023